|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: NTAN1 |
Gene summary for NTAN1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | NTAN1 | Gene ID | 123803 |
| Gene name | N-terminal asparagine amidase | |
| Gene Alias | PNAA | |
| Cytomap | 16p13.11 | |
| Gene Type | protein-coding | GO ID | GO:0006508 | UniProtAcc | A0A087X0T5 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 123803 | NTAN1 | LZE4T | Human | Esophagus | ESCC | 9.37e-05 | 1.60e-01 | 0.0811 |
| 123803 | NTAN1 | LZE8T | Human | Esophagus | ESCC | 4.96e-05 | 1.60e-01 | 0.067 |
| 123803 | NTAN1 | LZE24T | Human | Esophagus | ESCC | 6.99e-10 | 2.86e-01 | 0.0596 |
| 123803 | NTAN1 | LZE6T | Human | Esophagus | ESCC | 1.61e-03 | 1.26e-01 | 0.0845 |
| 123803 | NTAN1 | P1T-E | Human | Esophagus | ESCC | 9.27e-05 | 2.33e-01 | 0.0875 |
| 123803 | NTAN1 | P2T-E | Human | Esophagus | ESCC | 3.10e-21 | 4.03e-01 | 0.1177 |
| 123803 | NTAN1 | P4T-E | Human | Esophagus | ESCC | 1.21e-14 | 3.81e-01 | 0.1323 |
| 123803 | NTAN1 | P5T-E | Human | Esophagus | ESCC | 9.34e-12 | 2.52e-01 | 0.1327 |
| 123803 | NTAN1 | P8T-E | Human | Esophagus | ESCC | 1.26e-11 | 2.84e-01 | 0.0889 |
| 123803 | NTAN1 | P9T-E | Human | Esophagus | ESCC | 6.23e-05 | 1.91e-01 | 0.1131 |
| 123803 | NTAN1 | P10T-E | Human | Esophagus | ESCC | 3.38e-08 | 2.43e-01 | 0.116 |
| 123803 | NTAN1 | P11T-E | Human | Esophagus | ESCC | 4.83e-06 | 3.13e-01 | 0.1426 |
| 123803 | NTAN1 | P12T-E | Human | Esophagus | ESCC | 2.62e-23 | 5.35e-01 | 0.1122 |
| 123803 | NTAN1 | P15T-E | Human | Esophagus | ESCC | 2.45e-23 | 4.68e-01 | 0.1149 |
| 123803 | NTAN1 | P16T-E | Human | Esophagus | ESCC | 3.02e-12 | 2.95e-01 | 0.1153 |
| 123803 | NTAN1 | P17T-E | Human | Esophagus | ESCC | 2.58e-06 | 3.39e-01 | 0.1278 |
| 123803 | NTAN1 | P19T-E | Human | Esophagus | ESCC | 2.19e-07 | 6.59e-01 | 0.1662 |
| 123803 | NTAN1 | P20T-E | Human | Esophagus | ESCC | 3.07e-23 | 5.91e-01 | 0.1124 |
| 123803 | NTAN1 | P21T-E | Human | Esophagus | ESCC | 6.76e-50 | 1.08e+00 | 0.1617 |
| 123803 | NTAN1 | P22T-E | Human | Esophagus | ESCC | 2.63e-31 | 5.84e-01 | 0.1236 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| NTAN1 | SNV | Missense_Mutation | novel | c.209A>G | p.Asp70Gly | p.D70G | Q96AB6 | protein_coding | deleterious(0.03) | possibly_damaging(0.801) | TCGA-A8-A08J-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
| NTAN1 | SNV | Missense_Mutation | c.442N>C | p.Asp148His | p.D148H | Q96AB6 | protein_coding | tolerated(0.77) | benign(0.131) | TCGA-BH-A18P-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
| NTAN1 | insertion | Frame_Shift_Ins | novel | c.187dupT | p.Ser63PhefsTer8 | p.S63Ffs*8 | Q96AB6 | protein_coding | TCGA-A7-A0CE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | ||
| NTAN1 | insertion | Frame_Shift_Ins | novel | c.185_186insAGTCTCGGCCTGCGCACTGCACTCGCATCAGGGAATAA | p.Ser63ValfsTer31 | p.S63Vfs*31 | Q96AB6 | protein_coding | TCGA-A7-A0CE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | ||
| NTAN1 | SNV | Missense_Mutation | novel | c.578C>A | p.Ser193Tyr | p.S193Y | Q96AB6 | protein_coding | deleterious(0) | probably_damaging(0.919) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| NTAN1 | SNV | Missense_Mutation | novel | c.244C>T | p.His82Tyr | p.H82Y | Q96AB6 | protein_coding | deleterious(0) | benign(0.408) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| NTAN1 | insertion | Frame_Shift_Ins | rs780770021 | c.831dupA | p.His278ThrfsTer13 | p.H278Tfs*13 | Q96AB6 | protein_coding | TCGA-MU-A8JM-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | ||
| NTAN1 | SNV | Missense_Mutation | c.422A>G | p.His141Arg | p.H141R | Q96AB6 | protein_coding | tolerated(0.34) | benign(0.001) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| NTAN1 | SNV | Missense_Mutation | c.233N>G | p.Val78Gly | p.V78G | Q96AB6 | protein_coding | deleterious(0) | possibly_damaging(0.734) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| NTAN1 | SNV | Missense_Mutation | novel | c.461T>A | p.Ile154Asn | p.I154N | Q96AB6 | protein_coding | deleterious(0) | possibly_damaging(0.742) | TCGA-AG-A00Y-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |